Article | September 8, 2022

Quick Guide To Recent FDA Draft Guidelines: "Risk Management Plans To Mitigate The Potential For Drug Shortages"

By Kate Smith, Director of Quality, PCI Pharma Services

FDA Approved GettyImages-1215516118

Drug shortages can severely impact patients’ health, therefore global monitoring of drug product availability (human medicine and biologics) is an ongoing priority of Regulatory Agencies worldwide. This year the US Food and Drug Administration (FDA) drafted guidelines on best practice in aiding the prevention of shortages which may be caused by disruptions in the supply chain either by raw materials supply, manufacturing difficulties, or natural disasters such as hurricanes or the recent Covid-19 pandemic.

The FDA draft guidance outlines the need to "help stakeholders develop, maintain, and implement risk management plans (RMPs) to proactively assist in the prevention of human drug product and biological product shortages..." Learn more about these FDA draft guidelines in this quick reference guide developed by PCI’s Director of Quality, Kate Smith.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader